Literature DB >> 3105375

Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study.

M J Zervos, C A Kauffman, P M Therasse, A G Bergman, T S Mikesell, D R Schaberg.   

Abstract

Enterococci with high-level resistance to gentamicin account for 55% of clinical isolates of enterococci found in patients at the Ann Arbor Veterans Administration Medical Center. We prospectively studied cultures obtained from all 100 patients hospitalized from 1 December 1985 through 23 January 1986 on the surgical and thoracic intensive care units and a general medical floor. Ten patients' cultures grew colonies of gentamicin-resistant enterococci--six after admission to the intensive care units and four after hospitalization on the medical ward. The initial sites of colonization were the rectal and perineal areas in seven patients, sternal wound in one, urine in one, and the rectal and perineal areas as well as urine after Foley catheter insertion in one. Nine patients died and three of the deaths were associated with enterococcal infection. The acquisition of resistant strains was associated with previous and more frequent exposure to antimicrobial agents, and with geographic clustering of patients. Resistant enterococci were isolated from the hands of hospital personnel and were frequently isolated from environmental surfaces. Nosocomial acquisition and interhospital spread of gentamicin-resistant enterococci was shown to have occurred when plasmid content was used as an epidemiologic marker.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105375     DOI: 10.7326/0003-4819-106-5-687

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  94 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Characterization of enterococcal isolates by restriction enzyme analysis of genomic DNA.

Authors:  P A Lacoux; J Z Jordens; C M Fenton; M Guiney; T H Pennington
Journal:  Epidemiol Infect       Date:  1992-08       Impact factor: 2.451

3.  Increasing resistance of enterococci to ciprofloxacin.

Authors:  D R Schaberg; W I Dillon; M S Terpenning; K A Robinson; S F Bradley; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

4.  A multidisciplinary hospital-based antimicrobial use program: Impact on hospital pharmacy expenditures and drug use.

Authors:  S Salama; C Rotstein; L Mandell
Journal:  Can J Infect Dis       Date:  1996-03

5.  The enterococci: an enigma and a continuing therapeutic challenge.

Authors:  R C Moellering
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

6.  Molecular epidemiology of beta-lactamase-producing enterococci.

Authors:  J E Patterson; A Wanger; K K Zscheck; M J Zervos; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

7.  Activity of LY146032 against Enterococci with and without high-level aminoglycoside resistance, including two penicillinase-producing strains.

Authors:  A R Wanger; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

8.  In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.

Authors:  D F Sahm; J Kissinger; M S Gilmore; P R Murray; R Mulder; J Solliday; B Clarke
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

9.  Gentamicin-resistant enterococci and endocarditis.

Authors:  R Holliman; E Smyth
Journal:  Postgrad Med J       Date:  1989-06       Impact factor: 2.401

10.  Chromosomal DNA restriction endonuclease digestion patterns of beta-lactamase-producing Enterococcus faecalis isolates collected from a single hospital over a 7-year period.

Authors:  P S Seetulsingh; J F Tomayko; P E Coudron; S M Markowitz; C Skinner; K V Singh; B E Murray
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.